Expression  ||| S:0 E:11 ||| NN
of  ||| S:11 E:14 ||| IN
serum  ||| S:14 E:20 ||| CD
let-7c ||| S:20 E:26 ||| CD
,  ||| S:26 E:28 ||| ,
let-7i ||| S:28 E:34 ||| NNP
,  ||| S:34 E:36 ||| ,
and  ||| S:36 E:40 ||| CC
let-7f  ||| S:40 E:47 ||| CD
microRNA  ||| S:47 E:56 ||| NN
with  ||| S:56 E:61 ||| IN
its  ||| S:61 E:65 ||| PRP$
target  ||| S:65 E:72 ||| NN
gene ||| S:72 E:76 ||| NN
,  ||| S:76 E:78 ||| ,
pepsinogen  ||| S:78 E:89 ||| VBG
C ||| S:89 E:90 ||| NNP
,  ||| S:90 E:92 ||| ,
in  ||| S:92 E:95 ||| IN
gastric  ||| S:95 E:103 ||| JJ
cancer  ||| S:103 E:110 ||| NN
and  ||| S:110 E:114 ||| CC
precancerous  ||| S:114 E:127 ||| JJ
disease  ||| S:127 E:135 ||| NN
This  ||| S:135 E:140 ||| DT
study  ||| S:140 E:146 ||| NN
examined  ||| S:146 E:155 ||| VBD
the  ||| S:155 E:159 ||| DT
expression  ||| S:159 E:170 ||| NN
patterns  ||| S:170 E:179 ||| NNS
of  ||| S:179 E:182 ||| IN
serum  ||| S:182 E:188 ||| FW
let-7  ||| S:188 E:194 ||| FW
microRNA  ||| S:194 E:203 ||| FW
( ||| S:203 E:204 ||| -LRB-
miRNA ||| S:204 E:209 ||| NNP
)  ||| S:209 E:211 ||| -RRB-
and  ||| S:211 E:215 ||| CC
its  ||| S:215 E:219 ||| PRP$
target  ||| S:219 E:226 ||| NN
gene ||| S:226 E:230 ||| NN
,  ||| S:230 E:232 ||| ,
pepsinogen  ||| S:232 E:243 ||| VBG
C  ||| S:243 E:245 ||| NNP
( ||| S:245 E:246 ||| -LRB-
PGC ||| S:246 E:249 ||| NNP
) ||| S:249 E:250 ||| -RRB-
,  ||| S:250 E:252 ||| ,
in  ||| S:252 E:255 ||| IN
gastric  ||| S:255 E:263 ||| JJ
cancer  ||| S:263 E:270 ||| NN
( ||| S:270 E:271 ||| -LRB-
GC ||| S:271 E:273 ||| NNP
)  ||| S:273 E:275 ||| -RRB-
and  ||| S:275 E:279 ||| CC
precancerous  ||| S:279 E:292 ||| JJ
disease  ||| S:292 E:300 ||| NN
patients  ||| S:300 E:309 ||| NNS
to  ||| S:309 E:312 ||| TO
evaluate  ||| S:312 E:321 ||| VB
their  ||| S:321 E:327 ||| PRP$
diagnostic  ||| S:327 E:338 ||| JJ
efficiency  ||| S:338 E:349 ||| NN
for  ||| S:349 E:353 ||| IN
GC  ||| S:353 E:356 ||| NNP
and  ||| S:356 E:360 ||| CC
its  ||| S:360 E:364 ||| PRP$
precursor  ||| S:364 E:374 ||| NN
and  ||| S:374 E:378 ||| CC
to  ||| S:378 E:381 ||| TO
investigate  ||| S:381 E:393 ||| VB
any  ||| S:393 E:397 ||| DT
correlation  ||| S:397 E:409 ||| NN
between  ||| S:409 E:417 ||| IN
the  ||| S:417 E:421 ||| DT
two ||| S:421 E:424 ||| CD
.  ||| S:424 E:426 ||| .
Serum  ||| S:426 E:432 ||| JJ
samples  ||| S:432 E:440 ||| NNS
were  ||| S:440 E:445 ||| VBD
taken  ||| S:445 E:451 ||| VBN
from  ||| S:451 E:456 ||| IN
638  ||| S:456 E:460 ||| CD
patients ||| S:460 E:468 ||| NNS
,  ||| S:468 E:470 ||| ,
including  ||| S:470 E:480 ||| VBG
214  ||| S:480 E:484 ||| CD
GC  ||| S:484 E:487 ||| NN
patients ||| S:487 E:495 ||| NNS
,  ||| S:495 E:497 ||| ,
222  ||| S:497 E:501 ||| CD
atrophic  ||| S:501 E:510 ||| CD
gastritis  ||| S:510 E:520 ||| NNS
( ||| S:520 E:521 ||| -LRB-
AG ||| S:521 E:523 ||| NNP
)  ||| S:523 E:525 ||| -RRB-
patients ||| S:525 E:533 ||| NNS
,  ||| S:533 E:535 ||| ,
and  ||| S:535 E:539 ||| CC
202  ||| S:539 E:543 ||| CD
controls  ||| S:543 E:552 ||| NNS
( ||| S:552 E:553 ||| -LRB-
CON ||| S:553 E:556 ||| NNP
) ||| S:556 E:557 ||| -RRB-
.  ||| S:557 E:559 ||| .
The  ||| S:559 E:563 ||| DT
expression  ||| S:563 E:574 ||| NN
of  ||| S:574 E:577 ||| IN
serum  ||| S:577 E:583 ||| JJ
let-7  ||| S:583 E:589 ||| NNP
miRNA  ||| S:589 E:595 ||| NNP
was  ||| S:595 E:599 ||| VBD
detected  ||| S:599 E:608 ||| VBN
in  ||| S:608 E:611 ||| IN
control-AG  ||| S:611 E:622 ||| NNP
( ||| S:622 E:623 ||| -LRB-
precancerous  ||| S:623 E:636 ||| JJ
disease ||| S:636 E:643 ||| NN
)  ||| S:643 E:645 ||| -RRB-
through  ||| S:645 E:653 ||| IN
to  ||| S:653 E:656 ||| TO
GC  ||| S:656 E:659 ||| NNP
patients  ||| S:659 E:668 ||| NNS
using  ||| S:668 E:674 ||| VBG
quantitative  ||| S:674 E:687 ||| JJ
reverse-transcription  ||| S:687 E:709 ||| JJ
polymerase  ||| S:709 E:720 ||| JJ
chain  ||| S:720 E:726 ||| NN
reaction ||| S:726 E:734 ||| NN
.  ||| S:734 E:736 ||| .
Serum  ||| S:736 E:742 ||| NNP
PGC  ||| S:742 E:746 ||| NNP
was  ||| S:746 E:750 ||| VBD
determined  ||| S:750 E:761 ||| VBN
by  ||| S:761 E:764 ||| IN
enzyme-linked  ||| S:764 E:778 ||| JJ
immuno-sorbent  ||| S:778 E:793 ||| JJ
assay ||| S:793 E:798 ||| NN
.  ||| S:798 E:800 ||| .
PGC  ||| S:800 E:804 ||| NNP
expression  ||| S:804 E:815 ||| NN
in  ||| S:815 E:818 ||| IN
situ  ||| S:818 E:823 ||| NN
was  ||| S:823 E:827 ||| VBD
detected  ||| S:827 E:836 ||| VBN
by  ||| S:836 E:839 ||| IN
immunohistochemistry  ||| S:839 E:860 ||| JJ
staining ||| S:860 E:868 ||| NN
.  ||| S:868 E:870 ||| .
The  ||| S:870 E:874 ||| DT
luciferase  ||| S:874 E:885 ||| JJ
reporter  ||| S:885 E:894 ||| NN
gene  ||| S:894 E:899 ||| NN
system  ||| S:899 E:906 ||| NN
was  ||| S:906 E:910 ||| VBD
used  ||| S:910 E:915 ||| VBN
to  ||| S:915 E:918 ||| TO
verify  ||| S:918 E:925 ||| VB
correlation  ||| S:925 E:937 ||| VBN
between  ||| S:937 E:945 ||| IN
let-7  ||| S:945 E:951 ||| NNP
miRNA  ||| S:951 E:957 ||| NNP
and  ||| S:957 E:961 ||| CC
its  ||| S:961 E:965 ||| PRP$
predicted  ||| S:965 E:975 ||| JJ
target  ||| S:975 E:982 ||| NN
gene ||| S:982 E:986 ||| NN
.  ||| S:986 E:988 ||| .
The  ||| S:988 E:992 ||| DT
results  ||| S:992 E:1000 ||| NNS
showed  ||| S:1000 E:1007 ||| VBD
that  ||| S:1007 E:1012 ||| IN
serum  ||| S:1012 E:1018 ||| CD
let-7c ||| S:1018 E:1024 ||| CD
,  ||| S:1024 E:1026 ||| ,
let-7i ||| S:1026 E:1032 ||| NNP
,  ||| S:1032 E:1034 ||| ,
and  ||| S:1034 E:1038 ||| CC
let-7f  ||| S:1038 E:1045 ||| NNP
demonstrated  ||| S:1045 E:1058 ||| VBD
significant  ||| S:1058 E:1070 ||| JJ
differences  ||| S:1070 E:1082 ||| NNS
in  ||| S:1082 E:1085 ||| IN
the  ||| S:1085 E:1089 ||| DT
CON-AG-GC  ||| S:1089 E:1099 ||| JJ
sequence  ||| S:1099 E:1108 ||| NN
( ||| S:1108 E:1109 ||| -LRB-
P  ||| S:1109 E:1111 ||| NN
=  ||| S:1111 E:1113 ||| SYM
0.017 ||| S:1113 E:1118 ||| CD
,  ||| S:1118 E:1120 ||| ,
P  ||| S:1120 E:1122 ||| NNP
< ||| S:1122 E:1124 ||| SYM
0.001 ||| S:1124 E:1129 ||| NNP
,  ||| S:1129 E:1131 ||| ,
P  ||| S:1131 E:1133 ||| NN
=  ||| S:1133 E:1135 ||| SYM
0.003 ||| S:1135 E:1140 ||| CD
,  ||| S:1140 E:1142 ||| ,
respectively ||| S:1142 E:1154 ||| RB
) ||| S:1154 E:1155 ||| -RRB-
;  ||| S:1155 E:1157 ||| :
let-7c  ||| S:1157 E:1164 ||| NNP
was  ||| S:1164 E:1168 ||| VBD
significantly  ||| S:1168 E:1182 ||| RB
lower  ||| S:1182 E:1188 ||| JJR
in  ||| S:1188 E:1191 ||| IN
the  ||| S:1191 E:1195 ||| DT
AG  ||| S:1195 E:1198 ||| NNP
group ||| S:1198 E:1203 ||| NN
,  ||| S:1203 E:1205 ||| ,
and  ||| S:1205 E:1209 ||| CC
let-7i  ||| S:1209 E:1216 ||| NNP
and  ||| S:1216 E:1220 ||| CC
let-7f  ||| S:1220 E:1227 ||| NNP
were  ||| S:1227 E:1232 ||| VBD
significantly  ||| S:1232 E:1246 ||| RB
higher  ||| S:1246 E:1253 ||| JJR
in  ||| S:1253 E:1256 ||| IN
the  ||| S:1256 E:1260 ||| DT
GC  ||| S:1260 E:1263 ||| NNP
group ||| S:1263 E:1268 ||| NN
.  ||| S:1268 E:1270 ||| .
Significantly  ||| S:1270 E:1284 ||| RB
different  ||| S:1284 E:1294 ||| JJ
expressions  ||| S:1294 E:1306 ||| NNS
of  ||| S:1306 E:1309 ||| IN
serum  ||| S:1309 E:1315 ||| JJ
PGC  ||| S:1315 E:1319 ||| NNP
were  ||| S:1319 E:1324 ||| VBD
found  ||| S:1324 E:1330 ||| VBN
among  ||| S:1330 E:1336 ||| IN
the  ||| S:1336 E:1340 ||| DT
three  ||| S:1340 E:1346 ||| CD
diseases ||| S:1346 E:1354 ||| NNS
,  ||| S:1354 E:1356 ||| ,
and  ||| S:1356 E:1360 ||| CC
also  ||| S:1360 E:1365 ||| RB
between  ||| S:1365 E:1373 ||| IN
AG  ||| S:1373 E:1376 ||| NNP
vs.  ||| S:1376 E:1380 ||| FW
CON ||| S:1380 E:1383 ||| NNP
,  ||| S:1383 E:1385 ||| ,
and  ||| S:1385 E:1389 ||| CC
GC  ||| S:1389 E:1392 ||| NNP
vs.  ||| S:1392 E:1396 ||| FW
CON  ||| S:1396 E:1400 ||| FW
( ||| S:1400 E:1401 ||| -LRB-
P  ||| S:1401 E:1403 ||| NN
=  ||| S:1403 E:1405 ||| SYM
0.027 ||| S:1405 E:1410 ||| CD
,  ||| S:1410 E:1412 ||| ,
P  ||| S:1412 E:1414 ||| NN
=  ||| S:1414 E:1416 ||| SYM
0.001 ||| S:1416 E:1421 ||| CD
,  ||| S:1421 E:1423 ||| ,
respectively ||| S:1423 E:1435 ||| RB
) ||| S:1435 E:1436 ||| -RRB-
.  ||| S:1436 E:1438 ||| .
Linear-regression  ||| S:1438 E:1456 ||| JJ
analysis  ||| S:1456 E:1465 ||| NN
suggested  ||| S:1465 E:1475 ||| VBD
that  ||| S:1475 E:1480 ||| DT
serum  ||| S:1480 E:1486 ||| JJ
let-7c  ||| S:1486 E:1493 ||| NN
was  ||| S:1493 E:1497 ||| VBD
negatively  ||| S:1497 E:1508 ||| RB
correlated  ||| S:1508 E:1519 ||| VBN
to  ||| S:1519 E:1522 ||| TO
the  ||| S:1522 E:1526 ||| DT
expression  ||| S:1526 E:1537 ||| NN
of  ||| S:1537 E:1540 ||| IN
PGC  ||| S:1540 E:1544 ||| NNP
( ||| S:1544 E:1545 ||| -LRB-
r  ||| S:1545 E:1547 ||| LS
=  ||| S:1547 E:1549 ||| SYM
-0.096 ||| S:1549 E:1555 ||| CD
,  ||| S:1555 E:1557 ||| ,
P  ||| S:1557 E:1559 ||| NN
=  ||| S:1559 E:1561 ||| SYM
0.047 ||| S:1561 E:1566 ||| CD
) ||| S:1566 E:1567 ||| -RRB-
,  ||| S:1567 E:1569 ||| ,
and  ||| S:1569 E:1573 ||| CC
serum  ||| S:1573 E:1579 ||| CD
let-7c ||| S:1579 E:1585 ||| CD
,  ||| S:1585 E:1587 ||| ,
let-7i ||| S:1587 E:1593 ||| NNP
,  ||| S:1593 E:1595 ||| ,
and  ||| S:1595 E:1599 ||| CC
let-7f  ||| S:1599 E:1606 ||| NNP
showed  ||| S:1606 E:1613 ||| VBD
no  ||| S:1613 E:1616 ||| DT
association  ||| S:1616 E:1628 ||| NN
with  ||| S:1628 E:1633 ||| IN
PGC  ||| S:1633 E:1637 ||| NNP
expression  ||| S:1637 E:1648 ||| NN
in  ||| S:1648 E:1651 ||| IN
tissue ||| S:1651 E:1657 ||| NN
.  ||| S:1657 E:1659 ||| .
In  ||| S:1659 E:1662 ||| IN
addition ||| S:1662 E:1670 ||| NN
,  ||| S:1670 E:1672 ||| ,
serum  ||| S:1672 E:1678 ||| CD
let-7c ||| S:1678 E:1684 ||| CD
,  ||| S:1684 E:1686 ||| ,
let-7f ||| S:1686 E:1692 ||| NNP
,  ||| S:1692 E:1694 ||| ,
and  ||| S:1694 E:1698 ||| CC
let-7i  ||| S:1698 E:1705 ||| NNP
showed  ||| S:1705 E:1712 ||| VBD
significant  ||| S:1712 E:1724 ||| JJ
correlations  ||| S:1724 E:1737 ||| NN
with  ||| S:1737 E:1742 ||| IN
environment  ||| S:1742 E:1754 ||| NN
factors ||| S:1754 E:1761 ||| NNS
.  ||| S:1761 E:1763 ||| .
Serum  ||| S:1763 E:1769 ||| NNP
let-7c ||| S:1769 E:1775 ||| NNP
,  ||| S:1775 E:1777 ||| ,
let-7i ||| S:1777 E:1783 ||| NNP
,  ||| S:1783 E:1785 ||| ,
and  ||| S:1785 E:1789 ||| CC
let-7f  ||| S:1789 E:1796 ||| NNP
demonstrated  ||| S:1796 E:1809 ||| VBD
significant  ||| S:1809 E:1821 ||| JJ
differences  ||| S:1821 E:1833 ||| NNS
in  ||| S:1833 E:1836 ||| IN
the  ||| S:1836 E:1840 ||| DT
CON-AG-GC  ||| S:1840 E:1850 ||| JJ
disease  ||| S:1850 E:1858 ||| NN
sequence  ||| S:1858 E:1867 ||| NN
indicating  ||| S:1867 E:1878 ||| VBG
that  ||| S:1878 E:1883 ||| IN
let-7  ||| S:1883 E:1889 ||| NNP
miRNA  ||| S:1889 E:1895 ||| NNP
might  ||| S:1895 E:1901 ||| MD
have  ||| S:1901 E:1906 ||| VB
value  ||| S:1906 E:1912 ||| NN
by  ||| S:1912 E:1915 ||| IN
serving  ||| S:1915 E:1923 ||| VBG
as  ||| S:1923 E:1926 ||| IN
potential  ||| S:1926 E:1936 ||| JJ
biomarker  ||| S:1936 E:1946 ||| NN
in  ||| S:1946 E:1949 ||| IN
the  ||| S:1949 E:1953 ||| DT
diagnosis  ||| S:1953 E:1963 ||| NN
of  ||| S:1963 E:1966 ||| IN
GC  ||| S:1966 E:1969 ||| NNP
or  ||| S:1969 E:1972 ||| CC
its  ||| S:1972 E:1976 ||| PRP$
precancerous  ||| S:1976 E:1989 ||| JJ
diseases ||| S:1989 E:1997 ||| NNS
.  ||| S:1997 E:1999 ||| .
There  ||| S:1999 E:2005 ||| EX
were  ||| S:2005 E:2010 ||| VBD
significant  ||| S:2010 E:2022 ||| JJ
negative  ||| S:2022 E:2031 ||| JJ
correlations  ||| S:2031 E:2044 ||| NN
between  ||| S:2044 E:2052 ||| IN
serum  ||| S:2052 E:2058 ||| JJ
let-7c  ||| S:2058 E:2065 ||| NN
and  ||| S:2065 E:2069 ||| CC
its  ||| S:2069 E:2073 ||| PRP$
target  ||| S:2073 E:2080 ||| NN
gene  ||| S:2080 E:2085 ||| NN
PGC  ||| S:2085 E:2089 ||| NNP
expression ||| S:2089 E:2099 ||| NN
.  ||| S:2099 E:2101 ||| .
